Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusSTU:CU2 +0.86%78 EV-to-OCF is 246.82 as of Aug. 27, 2026. GuruFocus rates STU:CU2 with a GF Score™ of 78/100 and a GF Value™ of €1.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Cerus ranks worse than 98.12% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cerus's Enterprise Value is €491.2 Mil.
Cerus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €2.0 Mil. Therefore, Cerus's EV-to-OCF for today is 246.82.
The historical rank and industry rank for Cerus's EV-to-OCF or its related term are showing as below:
STU:CU2'
s EV-to-OCF Range Over the Past 10 Years
Min: -41.83 Med: -14.68 Max: 271
Current: 237.24
During the past 13 years, the highest EV-to-OCF of Cerus was 271.00. The lowest was -41.83. And the median was -14.68.
STU:CU2's EV-to-OCF is ranked worse than 98.12% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.695
vs STU:CU2: 237.24
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-27), Cerus's stock price is €2.34.
Cerus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.027. Therefore, Cerus's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cerus's share price for today is €2.34.
Cerus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cerus EV-to-OCF Related Terms
Cerus EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cerus's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cerus's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cerus's EV-to-OCF falls into.
Cerus's current Enterprise Value is €491.2 Mil.
Cerus's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (STU:CU2) has a EV-to-OCF of 246.82 as of Aug. 27, 2026. According to the industry distribution chart, Cerus ranks #836 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 98.1%.
Is Cerus' EV-to-OCF too high?
Cerus' current EV-to-OCF is 246.82. The Medical Devices & Instruments industry median EV-to-OCF is 7.70. Cerus' value of 246.82 is 3107.5% above this industry median. Based on the distribution chart, Cerus ranks #836 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' EV-to-OCF compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #836 out of 852 companies for EV-to-OCF. This places Cerus in the lower half of its industry. The industry median EV-to-OCF is 7.70. Cerus' value of 246.82 is 3107.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.70, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cerus's current EV-to-OCF of 246.82 is 3107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current EV-to-OCF is 246.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (STU:CU2) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €2.34 — trading 18.8% above its estimated fair value. The current EV-to-OCF is 246.82 and 3107.5% above the Medical Devices & Instruments industry median of 7.70. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cerus (STU:CU2), the current EV-to-OCF is 246.82 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (STU:CU2) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for STU:CU2:
EV-to-OCF: 246.82
GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
Industry Position: 3107.5% above the Medical Devices & Instruments median (#836 of 852)
No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for STU:CU2
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CU2 has been successfully added to your 
